(firstQuint)Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice.

 Patients with rheumatoid arthritis who started treatment with adalimumab in a normal clinical setting according to the product label were documented.

 The follow-up observation period was for 2 years and focused on safety information and maintenance of efficacy during a normal clinical setting.

 Follow-up with participants was via regular office visits at intervals as determined by routine clinical practice or as recommended by national guidelines.

.

 Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice@highlight

Observation of safety, tolerability and effectiveness of adalimumab (Humira) therapy in a large patient collective under everyday clinical conditions over 2 years.

